AtriCure (ATRC) reported quarterly earnings results on Thursday, Aug-4-2016. The company said it had a profit of $-0.26 Earnings per Share for the quarter. The results exceeded Wall Street expectations beating the analyst consensus estimate by $0.04. Analysts had a consensus of $-0.30. The company posted revenue of $39.70 million in the period, compared to analysts expectations of $39.84 million. The company’s revenue was up 21.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.18 EPS.
Many Wall Street Analysts have commented on AtriCure. AtriCure was Resumed by JMP Securities to “Mkt Outperform” on Jun 30, 2016.
AtriCure closed down -0.22 points or -1.45% at $15 with 1,75,412 shares getting traded on Tusday. Post opening the session at $15.17, the shares hit an intraday low of $14.97 and an intraday high of $15.31 and the price fluctuated in this range throughout the day.Shares ended Tusday session in Red.
In a different news, on Mar 9, 2016, Elizabeth D Krell (director) sold 10,000 shares at $16.91 per share price. According to the SEC, on Dec 7, 2015, Douglas J Seith (Chief Operating Officer) sold 5,000 shares at $21.55 per share price. On May 8, 2015, Karen P Robards (director) sold 2,650 shares at $22.18 per share price, according to the Form-4 filing with the securities and exchange commission.
AtriCure Inc. is a medical device company providing atrial fibrillation (Afib) solutions. The Company has three primary product lines for cardiac tissue ablation and a product line for left atrial appendage exclusion. The Company’s Isolator Synergy System which includes its Isolator Synergy clamps generator and switchbox is used for the treatment of persistent and long-standing persistent Afib in patients who are undergoing open concomitant coronary artery bypass grafting and valve replacement or repair. The cryoICE cryosurgery product line offers a range of both single use and reusable cryoablation devices. The AtriClip Left Atrial Appendage Exclusion System is designed to occlude the heart’s left atrial appendage (LAA). Its radiofrequency (RF) ablation products are indicated for the ablation of cardiac tissue. The Company sells enabling technologies including its Lumitip dissectors and Endoscopic Technologies Inc.’s (Estech) line of reusable cardiac surgery instruments.